KR102791419B1 - 세포 함유 의약 조성물 - Google Patents

세포 함유 의약 조성물 Download PDF

Info

Publication number
KR102791419B1
KR102791419B1 KR1020217037758A KR20217037758A KR102791419B1 KR 102791419 B1 KR102791419 B1 KR 102791419B1 KR 1020217037758 A KR1020217037758 A KR 1020217037758A KR 20217037758 A KR20217037758 A KR 20217037758A KR 102791419 B1 KR102791419 B1 KR 102791419B1
Authority
KR
South Korea
Prior art keywords
cells
macrophages
cell population
cell
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217037758A
Other languages
English (en)
Korean (ko)
Other versions
KR20220003564A (ko
Inventor
다카유키 아사하라
아만켈디 에이. 살베코프
마코토 세키
Original Assignee
세루아쿠시아 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 세루아쿠시아 가부시키가이샤 filed Critical 세루아쿠시아 가부시키가이샤
Publication of KR20220003564A publication Critical patent/KR20220003564A/ko
Application granted granted Critical
Publication of KR102791419B1 publication Critical patent/KR102791419B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020217037758A 2019-08-19 2019-08-19 세포 함유 의약 조성물 Active KR102791419B1 (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2019/032322 WO2021033247A1 (ja) 2019-08-19 2019-08-19 細胞含有医薬組成物

Publications (2)

Publication Number Publication Date
KR20220003564A KR20220003564A (ko) 2022-01-10
KR102791419B1 true KR102791419B1 (ko) 2025-04-08

Family

ID=74659865

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217037758A Active KR102791419B1 (ko) 2019-08-19 2019-08-19 세포 함유 의약 조성물

Country Status (4)

Country Link
US (1) US12460182B2 (cg-RX-API-DMAC7.html)
JP (1) JP7500083B2 (cg-RX-API-DMAC7.html)
KR (1) KR102791419B1 (cg-RX-API-DMAC7.html)
WO (1) WO2021033247A1 (cg-RX-API-DMAC7.html)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6372782B2 (ja) * 2012-09-28 2018-08-15 公益財団法人神戸医療産業都市推進機構 虚血性疾患治療に適した細胞を含む細胞群の生体外増幅方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014027474A1 (ja) 2012-08-17 2014-02-20 株式会社Clio 心筋梗塞の修復再生を誘導する多能性幹細胞
AU2015297347B2 (en) 2014-08-01 2021-05-27 PuREC Co., Ltd Method for evaluating quality of human mesenchymal stem cell, and monoclonal antibody for use in said method
US20160287638A1 (en) 2015-04-02 2016-10-06 Stemedica Cell Technologies, Inc. Ischemic tolerant cells and cellular factors in the treatment of peripheral artery disease
EP3297615A1 (en) * 2015-05-20 2018-03-28 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for modulation polarization and activation of macrophages
EP3299453B1 (en) * 2016-09-23 2019-05-08 Xcell Medical Solutions, S.L. Cell therapy with polarized macrophages for tissue regeneration

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6372782B2 (ja) * 2012-09-28 2018-08-15 公益財団法人神戸医療産業都市推進機構 虚血性疾患治療に適した細胞を含む細胞群の生体外増幅方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MASUDA H. et al., J. Am. Heart Assoc., 2014, vol. 3, e000743
Zhao Cheng et al., Bone marrow-derived innate macrophages attenuate oxazolone-induced colitis, Cellular Immunology 311 (2017) 46-53*

Also Published As

Publication number Publication date
JP7500083B2 (ja) 2024-06-17
KR20220003564A (ko) 2022-01-10
WO2021033247A1 (ja) 2021-02-25
JPWO2021033247A1 (cg-RX-API-DMAC7.html) 2021-02-25
US20220218744A1 (en) 2022-07-14
US12460182B2 (en) 2025-11-04

Similar Documents

Publication Publication Date Title
Dazzi et al. The role of mesenchymal stem cells in haemopoiesis
US10722541B2 (en) Methods for treating radiation or chemical injury
Tuder et al. Relevant issues in the pathology and pathobiology of pulmonary hypertension
US20140017209A1 (en) Methods for treating radiation or chemical injury
TW201130977A (en) Mesenchymal stem cells (MSCs) isolated from mobilized peripheral blood
BRPI0709349A2 (pt) métodos para expansão celular e usos de células e de meios condicionados produzidos através deles para terapia
KR20160131112A (ko) 간엽줄기세포 활성화제, 활성화된 간엽줄기세포 및 그 제조 방법
Swart et al. Mesenchymal stromal cells for treatment of arthritis
CN113853206A (zh) 脑梗塞的功能恢复
US6821513B1 (en) Method for enhancing hematopoiesis
Milazzo et al. Therapeutic efficacy of intracerebral hematopoietic stem cell gene therapy in an Alzheimer’s disease mouse model
US12178849B2 (en) Autoimmune disease treatment with chemokine-loaded alginate microparticles
AU2013235600B2 (en) Isolation and use of human lymphoid organ-derived suppressive stromal cells
JPWO2020158924A1 (ja) 母児間免疫寛容を誘導する方法
CN114901806A (zh) 细胞群以及其取得方法
US20200291109A1 (en) Composition to induce bone marrow stem cell mobilization
WO2022195117A1 (en) Mesenchymal stem cells for use in increasing ex-vivo organ life
van Os et al. Engraftment of syngeneic bone marrow is not more efficient after intrafemoral transplantation than after traditional intravenous administration
WO2014193895A1 (en) Ex vivo perfusion of donor organs prior to transplantation using mesenchymal stem cells
Norol et al. GFP-transduced CD34+ and Lin− CD34− hematopoietic stem cells did not adopt a cardiac phenotype in a nonhuman primate model of myocardial infarct
JP7500083B2 (ja) 細胞含有医薬組成物
Bonaros et al. CCR3-and CXCR4-mediated interactions regulate migration of CD34+ human bone marrow progenitors to ischemic myocardium and subsequent tissue repair
US20130287747A1 (en) Methods of Treating Acute Kidney Injury Using Mesenchymal Stem Cells
WO2009046058A1 (en) A method to amplify cardiac stem cells in vitro and in vivo
US20050232905A1 (en) Use of peripheral blood cells for cardiac regeneration

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601